LISETTE ARVIZU: Open Payments
NPI 1689454332 · SHERMAN OAKS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,745 in 98 payments from 16 companies in 2025. Trend: 2023 $1,345 · 2024 $2,873 · 2025 $2,745
Food & beverage: $2,745
| Company | Payments | Amount |
|---|---|---|
| Arcutis Biotherapeutics, Inc. | 20 | $721 |
| ABBVIE INC. | 18 | $347 |
| GENZYME CORPORATION | 9 | $306 |
| UCB, Inc. | 6 | $263 |
| Regeneron Healthcare Solutions, Inc. | 7 | $186 |
| Incyte Corporation | 9 | $167 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 7 | $156 |
| Janssen Biotech, Inc. | 5 | $132 |
| Novartis Pharmaceuticals Corporation | 6 | $130 |
| Galderma Laboratories, L.P. | 1 | $114 |
Products named: Zoryve, DUPIXENT, Bimzelx, SKYRIZI, OPZELURA, Winlevi, TREMFYA, NEMLUVIO.
Industry payments across CA — which companies pay providers there.
